COAG Study - Non-Contact Measurement of Whole Blood Coagulation in a Smoking “Well” population

COAG study aims to test the effectiveness of a non-contact method for measuring coagulation called acoustic tweezing thromboelastometry. This method, based on the acoustic levitation phenomenon, can measure the coagulation status of blood more accurately and quickerthan standard laboratory tests.

This study consists of a single visit, in which the Acoustic tweezing thromboelastometry test and standard coagulation assay test is performed on blood of healthy non-smoking and healthy smoking volunteers of ages 18 to 50 years.

 

All of US

At the moment, health care is one-size-fits-all. But imagine a future where your health treatments are individualized and as unique as you are. This is called precision medicine - and we can make that future possible.

Participants may be asked to:

  1. Answer Surveys Online
  2. Share your electronic health record (EHR)
  3. Give blood and urine samples
  4. Have your physical measurements taken

You can get started by visiting JoinAllofUs.org/Tulane or by calling us at (504) 988-0200.

all of us info 1

all of us info 2

 

 

RAGE Ruptured Aneurysms Treated with Hydrogel Coils

This is a prospective, non-randomized, multicenter post-market study. The RAGE study is designed to determine the safety and blockage rates of hydrogel coils in patients with ruptured aneurysms. The data from these procedures is collected and recorded for research purposes and includes clinical follow-up evaluations performed at 30 days (20 - 60 days) and 18 ± 6 months, and an angiogram follow-up evaluation will be performed at 18 ± 6 months.

 

The CHRONICLE Study: A Longitudinal Prospective Observational Study of the Characteristics, Treatment Patterns and Health Outcomes of Individuals with Severe Asthma in the United States

An observational study looking at severe asthma. Must be seen in Tulane pulmonology clinic by Dr. Nereida Parada.

Retrophin Study

A study looking to approve Chenodeoxycholic Acid (CADA) for the treatment of Cerebrotendinosous Xamathomatosis (CTX)